arbekacin inn semisynthetic aminoglycoside antibiotic derived kanamycin primarily used treatment infections caused multiresistant bacteria including methicillinresistant staphylococcus aureus arbekacin originally synthesized dibekacin hamao umezawa registered marketed japan since trade name arbekacin longer covered patent generic versions drug also available trade names decontasin blubatosine arbekacin approved treatment pneumonia sepsis caused methicillinresistant staphylococcus aureus mrsa synergistic effect betalactams arbekacin also holds promise treatment multidrugresistant gramnegative bacterial infections multidrugresistant pseudomonas aeruginosa acinetobacter aminoglycosides arbekacin work binding bacterial ribosomal subunit causing misreading trna consequently leaves bacterium unable synthesize proteins vital growth energy needed aminoglycoside uptake bacterial cell anaerobes less energy available uptake aminoglycosides less active anaerobescitation needed aminoglycosides arbekacin inhibit protein synthesis susceptible bacteria irreversibly binding bacterial ribosomal subunit specifically arbekacin binds four nucleotides rrna single amino acid protein interferes decoding site vicinity nucleotide rrna component subunit region interacts wobble base anticodon trna leads misreading mrna incorrect amino acids inserted polypeptide leading nonfunctional toxic peptides breakup polysomes nonfunctional monosomescitation needed aminoglycosides well absorbed gastrointestinal tract typically administered parenterallycitation needed ototoxicity nephrotoxicity serious adverse effects aminoglycoside therapy likely occur patients history renal impairment receiving ototoxic andor nephrotoxic drugs normal duration intramuscular intravenous aminoglycoside therapy days though longer treatment sometimes necessary toxicity likely occur aminoglycoside treatment continued longer dayscitation needed httpsenwikipediaorgwikiarbekacin